Folliculitis Clinical Trial
Official title:
Placebo-controlled Trial Investigating the Effect of Vitamin K3-lotion for the Treatment of Cetuximab Induced Folliculitis
NCT number | NCT01094444 |
Other study ID # | 09.15 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | May 2010 |
Est. completion date | November 2014 |
Verified date | November 2020 |
Source | Odense University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study aims to explore the benefit of topical vitamin K3 lotion for the reactivation/rephosphorylation of EGF-receptor in the skin and the possible reduction in cutaneous side effects of EGFr-inhibition. Primary aim: The possible reduction of cutaneous side effects: folliculitis, dryness and redness of the skin. Secondary aim: To explore any possible side effects of topical vitamin K3 lotion. Methods: 36 patients with metastatic colorectal cancer or metastatic head and neck cancer allocated to treatment with chemotherapy and biweekly cetuximab. Two equally sized areas of at least 10x10 cm on the back or chest of the patient is marked. Patients receive in a double blinded procedure placebo lotion on one side and vitamin K3 lotion on the other side. The treatment may last for a maximum of two months and the patients are followed biweekly with photos, VAS-scores, questionnaires and CTCAE estimations. The patient will be able to take weekly photos at home during the weeks they are not seen at the outpatient clinic. During the treatment all other skin products or antibiotics is allowed and will be carefully registered by the health care professionals in the outpatient clinic. The patient may enter the trial in two different ways: 18 patients start treatment with study lotions at the time they start treatment with cetuximab. The other 18 patients start treatment with study lotions when folliculitis appears. Patients are asked for 1.5 mm skin biopsies of both study areas of the skin before start of treatment and after 4 weeks of treatment with placebo lotion and vitamin K3 lotion. These biopsies will be investigated for EGFr, phosphorylated EGFr and other central downstream mechanisms. The biopsy part of the study is optional for the patient.
Status | Completed |
Enrollment | 30 |
Est. completion date | November 2014 |
Est. primary completion date | December 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Planned or ongoing treatment with cetuximab - Age at least 18 years - Informed written consent according to local and national legislation Exclusion Criteria: - Known disease that can influence either treatment, evaluation and the outcome of the current disease and treatment, including chronic dermatology - Known hypersensitivity to menadion - Concomitant treatment with Vitamin K or Vitamin K-antagonists - Known psychological, family, sociological or geographic conditions which potentially can influence planned study treatment or follow-up |
Country | Name | City | State |
---|---|---|---|
Denmark | Odense University Hospital | Odense C |
Lead Sponsor | Collaborator |
---|---|
Per Pfeiffer |
Denmark,
Eriksen JG, Kaalund I, Clemmensen O, Overgaard J, Pfeiffer P. Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash. Support Care Cancer. 2017 Jul;25(7):2179-2185. doi: 10.1007/s00520-017-3623-x. Epub 2017 Feb 15. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Potential reduction in skin toxicity by vitamin K3 lotion | Reduction in numbers of papulo-pustular eruptions in the treatment fields. Changes in follicular eruptions, dryness/redness of skin estimated by CTCAE 4.0. Patients own experience of efficacy estimated by questionaire and VAS scale. | 3 months | |
Secondary | Potential toxicity of vitamin K3 lotion | No systemic or skin toxicity is expected. Therefore all experienced skin changes will be estimated by CTCAE 4.0. Furthermore, broad bloodtest screenings will be done bi-weekly. | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00746109 -
Study of Wound Packing After Superficial Skin Abscess Drainage
|
Phase 4 | |
Completed |
NCT00352612 -
Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections
|
Phase 4 | |
Completed |
NCT05345093 -
Evaluation of Safety and Performance of Ialuxid Gel in Treatment of Acne Vulgaris, and Folliculitis
|
N/A | |
Completed |
NCT06052241 -
Artificial Intelligence-based Prescription of Personalized Scalp Cosmetics
|
N/A | |
Completed |
NCT00289588 -
An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers
|
N/A | |
Completed |
NCT05793164 -
Characterization and Risk Factors of Folliculitis After Hair Transplantation
|
||
Completed |
NCT01126268 -
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
|
Phase 4 | |
Suspended |
NCT01244256 -
Efficacy and Comparative of the Association Beclomethasone Clotrimzaol + Gentamicin in Patients With Acne Contaminated
|
Phase 2/Phase 3 |